BlossomHill Therapeutics Completes $150M IPO

What Happened

• On August 10, 2026, BlossomHill Therapeutics, Inc. (BLSM) filed an 8-K reporting the closing of its initial public offering. The company sold 9,375,000 shares of common stock at $16.00 per share.
• In connection with the IPO, BlossomHill filed an amended and restated certificate of incorporation with the Delaware Secretary of State and adopted amended and restated bylaws; both were approved by the board and stockholders and became effective immediately prior to the IPO closing.

Key Details

• IPO size: 9,375,000 shares sold at $16.00 per share.
• Gross proceeds: approximately $150.0 million (before underwriting discounts/commissions and estimated offering expenses).
• Corporate changes: Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws filed/effective August 10, 2026 (Exhibits 3.1 and 3.2 to the 8-K).
• SEC filing date: Form 8-K filed August 10, 2026 (items reported include Items 5.03 and 8.01).

Why It Matters

• The company is now publicly listed (ticker BLSM), which increases regulatory disclosure and corporate governance obligations and provides public-market liquidity for shareholders.
• The IPO generated substantial gross proceeds (~$150.0M), which the company reported before underwriting fees and offering expenses—funds that can affect its cash position and operational plans going forward.